Overview

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a control to patients receiving low-dose aspirin and thereby examine the superiority of E3810 over Teprenone.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Aspirin
Geranylgeranylacetone
Rabeprazole